NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/16/2026
Back to search
Official data from USPTO
CONFO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
06/16/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
11/21/2022
Registration date
06/16/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2026
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
ZWIJNAARDE, BE
Examiner
SPRUILL, DARRYL M
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CONFO THERAPEUTICS NV
Confo Therapeutics N.V.
Representatives
Maury M. Tepper, III TEPPER & EYSTER, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substancesantibodies for stabilization of proteinsall the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); Chemical substances for use in the production of drugs; Biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; Chimeric proteins to measuretest and develop compounds and ligands binding to G protein-coupled receptors (GPCRs)
Class 5
Pharmaceutical and veterinary preparations for use in oncology and in the field of immunologypharmaceutical and veterinary preparations for treating immune-related diseases; pharmaceutical and veterinary preparations for the treatment of inflammatory diseases and infections and for the treatment of gastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatological and musculo-skeletal conditions and for the treatment of orphan diseases; chemical and biochemical substances for pharmaceutical and veterinary use in the nature of stabilized protein arrayssmall molecules and antibodies for diagnostic purposes for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary productsantibody reagents used for the detection of antigens in cells and tissue for medical purposes; veterinary productsantibody reagents for therapeutic use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary productssmall molecules in the form of low molecular weight organic compounds; veterinary productsbiological preparations for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatological and musculo-skeletal conditions and for the treatment of orphan disease
Class 42
Medical and pharmacological research services; Pharmaceutical drug development services; Laboratory research services relating to pharmaceuticals; Research and development of vaccines and medicines; Scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); Design of computer databases; Updating of database software; Data warehousing; Provision of information and data relating to medical research and development; Rendering of computer graphics featuring digital image correction for research and development; Computer graphic design services featuring data and image processing services for making three dimensional models; Non-medical graphic design featuring digital imaging services; Optical imaging for use in research and development of medicines; Imaging via computers for use in research and development of medicines; Graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines
Publications
History of USPTO decisions and trademark events.
37 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/28/2026
PUBO
PUBLISHED FOR OPPOSITION
04/28/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/22/2026
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
04/03/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/25/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/25/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/25/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/25/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/03/2026
GNRT
NON-FINAL ACTION E-MAILED
02/03/2026
CNRT
NON-FINAL ACTION WRITTEN
02/03/2026
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/02/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/11/2025
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
02/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/07/2025
PUBO
PUBLISHED FOR OPPOSITION
01/07/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/01/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/19/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/19/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/19/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/21/2024
GNRT
NON-FINAL ACTION E-MAILED
08/21/2024
CNRT
NON-FINAL ACTION WRITTEN
08/21/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/22/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/22/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/22/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
01/23/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
01/23/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/24/2023
GNRT
NON-FINAL ACTION E-MAILED
10/24/2023
CNRT
NON-FINAL ACTION WRITTEN
10/24/2023
DOCK
ASSIGNED TO EXAMINER
09/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/12/2022
NWAP
NEW APPLICATION ENTERED
11/24/2022
Continuous trademark protection
Get notified about every new filing that threatens CONFO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.